The Epidemiology of Second Primary Cancers
暂无分享,去创建一个
[1] V. Vogel. Identifying and Screening Patients at Risk of Second Cancers , 2006, Cancer Epidemiology Biomarkers & Prevention.
[2] A. Hagenbeek,et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. , 1995, Journal of the National Cancer Institute.
[3] F. Wilner,et al. Combination chemotherapy in the treatment of advanced Hodgkin's disease. , 1975, Michigan medicine.
[4] J. Allan,et al. Mechanisms of therapy-related carcinogenesis , 2005, Nature Reviews Cancer.
[5] A. Broeks,et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. , 2003, Journal of the National Cancer Institute.
[6] Erik Holmberg,et al. Radiation Effects on Breast Cancer Risk: A Pooled Analysis of Eight Cohorts , 2002, Radiation research.
[7] L. Travis,et al. Body wars: effect of friendly fire (cancer therapy) , 1995, Journal of the National Cancer Institute.
[8] P. Hall,et al. Long-term cause-specific mortality among 41,146 one-year survivors of Hodgkin lymphoma (HL) , 2005 .
[9] J. Yahalom. Breast cancer after Hodgkin disease: hope for a safer cure. , 2003, JAMA.
[10] P. Hall,et al. Treatment-associated leukemia following testicular cancer. , 2000, Journal of the National Cancer Institute.
[11] M. Stovall,et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. , 2003, JAMA.
[12] S. Raimondi,et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. , 1995, Leukemia.
[13] R. Platzman,et al. What is ionizing radiation? , 1959, Scientific American.
[14] T. Lancet. Cancer survivors: living longer, and now, better , 2004, The Lancet.
[15] A Kreuger,et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Gail,et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. , 2005, Journal of the National Cancer Institute.
[17] R N Hoover,et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. , 1992, The New England journal of medicine.
[18] M. Burke. Multiple Primary Cancers , 1936 .
[19] L. Robison,et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] 岩崎 民子. SOURCES AND EFFECTS OF IONIZING RADIATION : United Nations Scientific Committee on the Effects of Atomic Radiation UNSCEAR 2000 Report to the General Assembly, with Scientific Annexes , 2002 .
[21] J. Friedberg,et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. , 2002, Blood.
[22] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[23] E. Morgan,et al. Late effects of cancer therapy. , 1997, Cancer treatment and research.
[24] S. Mayne,et al. Chemoprevention : Second Cancer versus Primary Cancer Prevention Trials , 2006 .
[25] M. Stovall,et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Hagenbeek,et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. , 1995, Journal of the National Cancer Institute.
[27] L. Travis. Therapy-associated Solid Tumors , 2002, Acta oncologica.
[28] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[29] A. Hagenbeek,et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[31] John D Boice,et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.
[32] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .
[33] S. Bhatia. Cancer survivorship--pediatric issues. , 2005, Hematology. American Society of Hematology. Education Program.
[34] D. Longo. Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory? , 2005, Journal of the National Cancer Institute.
[35] Heikki Joensuu,et al. Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients. , 2006, Journal of the National Cancer Institute.
[36] M. Henry-Amar. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] C. Pui,et al. Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. , 2006, Journal of the National Cancer Institute.
[38] J. Fraumeni,et al. Cancer epidemiology and prevention. , 2006 .
[39] P. Hall,et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. , 1999, The New England journal of medicine.
[40] N. Day,et al. Leukemia following Hodgkin's disease. , 1990, The New England journal of medicine.
[41] John D Boice,et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. , 2002, Journal of the National Cancer Institute.
[42] D. Hossfeld. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .
[43] J. Connors,et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] C. Willett,et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease , 1997, Cancer.
[45] J. Jais,et al. Fifteen‐year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high‐dose irradiation , 2002, British journal of haematology.
[46] J. Fraumeni,et al. Lung Cancer after Treatment for Hodgkin's Disease: Focus on Radiation Effects , 2003, Radiation research.
[47] H. B. Marsden,et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. , 1996, Journal of the National Cancer Institute.
[48] D. Arthur,et al. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. , 1985, Blood.
[49] N. Breslow,et al. Second malignant neoplasms following treatment for Wilm's tumor: a report from the National Wilms' Tumor Study Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] T. Lister,et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] F. Behm,et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. , 2003, Blood.